CHAPTER 5 Dosage Form Design: Biopharmaceutical and Pharmacokinetic Considerations 161 REFERENCES 1. Cogburn JN, Donovan MG, Schasteen CS. A model of human small intestinal absorptive cells 1: Transport barrier. Pharm Res 1991;8:210-216. 2. Christensen FN, et al. The use of gamma scintigraphy to follow the gastrointestinal transit of pharmaceutical formulations. J Pharm Pharmacol 1985;37:91-95. 3. Coupe AJ, Davis SS, Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res 1991;8:360-364. 4. Poole J, Owen G, Silverio J. Physiochemical factors influencing the absorption of the anhydrous and trihydrate forms of ampicillin. Curr Ther Res Clin Exp 1968; 10:292-303. 5. Code of Federal Regulations, Title 21, Part 320. Bioavailability and Bioequivalence Requirements, 2012 ( updated). Available at: http:// www.accessdata.fda.gov/ scripts/ cdrh/ cf docs/ cfcfr / CFRSearch. cfm?CFRPart. (Accessed April 17, 2016) 6. Chatlos DJ, DiSanto AR. Basics of Bioavailability. Kalamazoo, MI: Upjohn, 1973. 7. Smith HJ. Process of drug handling by the body. Introduction to the Principles of Drug Design. 2nd Ed. London: Butterworth, 1988. 8. Cooper JW. Monitoring of drugs and hepatic status. Clinical Consult 1991;10(6):1991. 9. Vancomycin dosing and monitoring in adults. Available at: www. cumc.columbia.edu/ dept/id/ documents/vancomycindosingandÂ­ monitoringinadultpatients.pdf. (Accessed: April 17, 2016)